This Program Project, """"""""Hormonal Control of Calcium Metabolism,"""""""" brings together investigators from multiple disciplines to advance understanding of the actions of parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP). There is a new focus on heterogeneity of ligand/receptor conformations with surprising biological implications, novel cellular systems, and emphasis on genetically modified rodent models that reveal specific cellular controls. Together, these approaches provide insight into previously unappreciated basic mechanisms of PTH action that in turn can lead to changes in therapy of metabolic bone disease and disorders of mineral homeostasis. Project I, """"""""PTH and PTHrP Interaction with PTH Receptors"""""""" (Thomas Gardella, PI), will address the divergent mechanisms used by PTH and PTHrP (and related designed analogs) to change the conformation of the PTH/PTHrP receptor in ways that alter signal activation within target cells. Project II, """"""""Genetic Analysis of Second Messengers in PTH Signaling in Bone"""""""" (Henry Kronenberg, PI), will use genetically altered mice that permit separate analyses of the roles of activation of adenylate cyclase versus phospholipase C activation by receptors on cells of the osteoblast lineage. Project III, """"""""Second Messengers in PTH Action"""""""" (F. Richard Bringhurst, PI), will use genetically altered mice and in vitro studies to address recently identified roles of protein kinase C d and the transcriptiorial co-regulator CITED1 in mediating the actions of PTH on bone. Project IV, """"""""Renal Regulation of Phosphate and Calcium Homeostasis"""""""" (Harold Juppner and Matthew Mahon, co-Pis) will use (1) genetically altered mice with selective alteration of mineral ion renal responses of PTH in vivo to determine the mechanisms by which PTH regulates renal mineral ion metabolism;and (2) newly developed selectively modified cell models of renal tubular action in vitro that examine the molecular basis of the phenotypes of the genetically altered mice, with a particular focus on the role of specific components of cellular cytoarchitecture in phosphate homeostasis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK011794-44
Application #
8207298
Study Section
Special Emphasis Panel (ZDK1-GRB-9 (O1))
Program Officer
Malozowski, Saul N
Project Start
1997-08-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
44
Fiscal Year
2012
Total Cost
$1,679,104
Indirect Cost
$711,368
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Bi, Ruiye; Fan, Yi; Lauter, Kelly et al. (2016) Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog. J Bone Miner Res 31:975-84
Stevenson, Hilary P; Lin, Guowu; Barnes, Christopher O et al. (2016) Transmission electron microscopy for the evaluation and optimization of crystal growth. Acta Crystallogr D Struct Biol 72:603-15
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2016) Sclerostin Antibody Administration Converts Bone Lining Cells into Active Osteoblasts. J Bone Miner Res :
Wein, Marc N; Liang, Yanke; Goransson, Olga et al. (2016) SIKs control osteocyte responses to parathyroid hormone. Nat Commun 7:13176
Eda, Homare; Santo, Loredana; Wein, Marc N et al. (2016) Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res 31:1225-34
Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon et al. (2016) Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. J Biol Chem 291:1631-42
Tenhola, Sirpa; Voutilainen, Raimo; Reyes, Monica et al. (2016) Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation. Eur J Endocrinol 175:211-8
Cheloha, Ross W; Watanabe, Tomoyuki; Dean, Thomas et al. (2016) Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist. ACS Chem Biol 11:2752-2762
Hattersley, Gary; Dean, Thomas; Corbin, Braden A et al. (2016) Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 157:141-9

Showing the most recent 10 out of 195 publications